Scholar Rock Holding Net Profit Margin 2017-2022 | SRRK

Scholar Rock Holding net profit margin from 2017 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Scholar Rock Holding Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.05B $-0.11B -240.43%
2021-12-31 $0.02B $-0.13B -700.00%
2021-09-30 $0.02B $-0.12B -688.89%
2021-06-30 $0.02B $-0.11B -687.50%
2021-03-31 $0.02B $-0.10B -653.33%
2020-12-31 $0.02B $-0.09B -580.00%
2020-09-30 $0.02B $-0.07B -360.00%
2020-06-30 $0.02B $-0.06B -290.91%
2020-03-31 $0.02B $-0.06B -252.17%
2019-12-31 $0.02B $-0.05B -247.62%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.174B $0.019B
Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00